secwatch.observer — SEC 8-K summary
======================================

Issuer:     Merck & Co., Inc. (MRK)
CIK:        0000310158
Form:       8-K
Filed at:   2025-10-30T23:59:59+00:00
Accession:  0001104659-25-103974
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Merck Q3 GAAP EPS $2.32, non-GAAP $2.58; raises full-year non-GAAP EPS guidance to $8.93-8.98
--------------------------------------------------------------------------------

- Total sales $17.3B (+4% YoY, +3% ex-FX); GAAP net income $5.8B, non-GAAP $6.4B.
- KEYTRUDA sales $8.1B (+10%); WINREVAIR $360M (+141%); GARDASIL down 24% to $1.7B.
- Full-year 2025 sales guidance raised to $64.5-65.0B; non-GAAP EPS raised to $8.93-8.98.
- Completed acquisition of Verona Pharma (OHTUVAYRE) in October 2025.
- FDA approved KEYTRUDA QLEX subcutaneous injection for all solid tumor indications.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/310158/000110465925103974/0001104659-25-103974-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/310158/000110465925103974/tm2529620d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-103974

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer